Charles River Drops WuXi PharmaTech Days Before Crucial Shareholder Vote; What Does the Future Hold For Both Firms?
This article was originally published in The Pink Sheet Daily
Executive Summary
Left at the altar by the U.S. CRO, WuXi gets a $30 million break up fee while Charles River likely will continue looking to build out its business in ways more appealing to shareholders.